BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26808421)

  • 21. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
    Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
    Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A comparative study on serum immunoglobulin and tumor marker levels in the patients with autoimmune pancreatitis and pancreatobiliary malignancies].
    Yoon H; Kim MH; Won SH; Park DH; Lee SS; Seo DW; Lee SK
    Korean J Gastroenterol; 2013 Jun; 61(6):327-32. PubMed ID: 23877213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
    Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
    World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin.
    Yan T; Ke Y; Chen Y; Xu C; Yu C; Li Y
    PLoS One; 2017; 12(4):e0174735. PubMed ID: 28369140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
    Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
    J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Ibrahim DA; Abouhashem NS
    Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
    Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
    Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
    Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.